Mawdsleys and Oncoscience launch a Named Patient Program for CIMAher® (Nimotuzumab) in the UK and Ireland

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites.
Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. For avoidance of any doubts and to make it easier, you may consider any links to external websites as sponsored links. Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Mawdsleys and Oncoscience GmbH have launched a Named Patient Supply Program to allow Oncologists in the United Kingdom (UK) and Ireland to obtain access to CIMAher (Nimotuzumab) on an unlicensed basis for the treatment of various types of cancer.

Nimotuzumab has been approved for marketing in 25 different countries worldwide for a variety of cancers. These approvals have been granted for the following indications: locally advanced or metastatic pancreatic cancer (adenocarcinoma), nasopharyngeal carcinoma, oesophageal cancer, lung cancer, high-malignant glial cancers (glioblastoma multiforme and anaplastic astrocytoma) and head & neck cancers in advanced stages. Nimotuzumab has also been approved in a number of countries for high-grade gliomas in children and adolescents (newly diagnosed, recurrent and refractory).

The EMEA granted orphan drug designation status for Nimotuzumab for the indications of glioma in 2004 and pancreatic cancer in 2008. Nimotuzumab has also received the US FDA orphan drug designation status for both indications.

The Named Patient Program for the UK and Ireland, which will be managed by Mawdsleys, will allow physicians access to CIMAher for patients who meet pre-specified medical criteria. Mawdsleys Director of Specialty Pharma, David Regan, comments We are pleased to be working with Oncoscience to create access to CIMAher for patients in the UK and Ireland and so help address a current unmet medical need in the treatment of certain advanced cancers.

Healthcare professionals can obtain further details about the Nimotuzumab Named Patient Program using the contact details below.


About CIMAher (Nimotuzumab)

Nimotuzumab is a humanized monoclonal antibody (mAb) that targets the epidermal growth factor receptor (EGFR). To date Nimotuzumab has been administered to more than 65,000 patients globally and is approved in 25 countries for multiple cancer types. Nimotuzumab is a well investigated mAb for treatment of tumours of epithelial origin as it has been published in more than 130 scientific peer review journals and involved in 92 clinical studies around the world.

About Mawdsleys

Founded in 1825, Mawdsleys is a privately-owned pharmaceutical services company based in the UK with operations in Brazil and Israel. We deliver a wide range of services to both the pharmaceutical industry and healthcare sector through our main business areas which include: Named Patient Medicines (delivering global named patient programmes), Product Licensing and Market Access (In the EU, LATAM and Middle East regions), UK Wholesale (largest independent wholesaler to UK hospitals), UK Pre-wholesale (3PL and 4PL services in the UK), LUTO (healthcare communications) and Positive Solutions (pharmacy IT systems).

About Oncoscience GmbH

Oncoscience is a Germany based privately-owned biopharmaceutical company founded in 2001 to advance the development of novel products for the treatment of orphan indications in oncology. Oncoscience has the exclusive rights for the anti-EGFR monoclonal antibody Nimotuzumab, in the European Union and the surrounding area (in total 46 countries). Oncoscience is committed to further developing Nimotuzumab in Europe to address oncological diseases for which the unmet medical need is high and for which effective and safe therapy is urgently needed.

Mike Rawlings, Head of Commercial Operations
+44 (0) 161 742 3359
E: [email protected]